Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Zolpidem Tartrate Clear all
Completed Not applicable Interventional Results available

Sequenced Therapies for Comorbid and Primary Insomnias

NCT01651442
View directory record Official record
Conditions
Insomnia Comorbid to Psychiatric Disorder, Primary Insomnia
Interventions
Behavioral Insomnia Therapy, Zolpidem, Trazodone, Cognitive Therapy
Behavioral · Drug
Lead sponsor
Jack Edinger, PhD
Other
Eligibility
21 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)

NCT00425243
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
zolpidem-MR (SL800750)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2009 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Role of Sleep in the Treatment of Cannabis Use Disorders

NCT01685073
View directory record Official record
Conditions
Drug Addiction
Interventions
Zolpidem extended-release, MET/CBT
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

NCT03056053
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Zolpidem
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Santa Monica, California • Atlanta, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

NCT01463098
View directory record Official record
Conditions
Insomnia
Interventions
E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Two Contrasting Interventions for Sleep Management

NCT01804036
View directory record Official record
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
Zolpidem, Mind-Body Bridging
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
17 Years to 40 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

NCT00893269
View directory record Official record
Conditions
Marijuana Dependence
Interventions
eszopiclone, Placebo, ramelteon, zolpidem
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 29, 2026, 2:11 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia

NCT00466193
View directory record Official record
Conditions
Insomnia
Interventions
zolpidem tartrate sublingual tablet, Placebo
Drug
Lead sponsor
Transcept Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Not applicable Interventional Results available

Orthostatic Hypotension Treatment on Rehab Unit

NCT01030874
View directory record Official record
Conditions
Orthostatic Hypotension, Falls
Interventions
Medication review, Nutrition/Salt intake, Education, Exercise, Drug Recommendations
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 4 Interventional Results available

Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia

NCT03774810
View directory record Official record
Conditions
Insomnia, Insomnia Chronic
Interventions
Zolpidem tartrate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 29, 2026, 2:11 PM EDT
Recruiting Phase 2 Interventional

Trial of Zolpidem for Sleep in Children With Autism

NCT05540574
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Zolpidem, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

NCT03375203
View directory record Official record
Conditions
Insomnia Disorders
Interventions
Placebo, JNJ-42847922, 5 mg, JNJ-42847922, 10 mg, JNJ-42847922, 20 mg, Zolpidem
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

NCT04009577
View directory record Official record
Conditions
Insomnia
Interventions
LEM 5 mg, LEM 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Glendale, Arizona • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Not applicable Interventional

Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer

NCT00084669
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Sleep Disorders
Interventions
venlafaxine, zolpidem tartrate, management of therapy complications
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Early Phase 1 Interventional

Proton MRS Study of SSRI-Zolpidem Interactions

NCT01809626
View directory record Official record
Conditions
Depression
Interventions
Zolpidem, Placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multimodal Sleep Pathway for Shoulder Arthroplasty

NCT03269760
View directory record Official record
Conditions
Sleep Disturbance, Shoulder Arthritis, Arthroplasty Complications, Perioperative/Postoperative Complications
Interventions
Zolpidem
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 4 Interventional

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

NCT04014387
View directory record Official record
Conditions
Progressive Supranuclear Palsy(PSP), Insomnia
Interventions
Suvorexant, Zolpidem, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance

NCT01243060
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Almorexant, Zolpidem 10mg, Placebo
Drug
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
19 Years to 39 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2014 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

NCT02783729
View directory record Official record
Conditions
Insomnia
Interventions
Lemborexant, Lemborexant-matched placebo, Zolpidem tartrate, Zolpidem-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
60
States / cities
Jasper, Alabama • Glendale, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions

NCT00833937
View directory record Official record
Conditions
Healthy
Interventions
Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Not applicable Interventional Results available

Zolpidem CR and Hospitalized Patients With Dementia

NCT00814502
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Dementia, Vascular, Sleep Disorders, Circadian Dysregulation
Interventions
Zolpidem CR, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 29, 2026, 2:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Zolpidem 10mg Tablets Under Fasting Conditions

NCT00779051
View directory record Official record
Conditions
Healthy
Interventions
Zolpidem 10mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Sep 29, 2026, 2:11 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 29, 2026, 2:11 PM EDT